Source - SMW
ReNeuron Group has provided an update on the Phase II clinical trial of its CTX cell therapy candidate for stroke disability.

The company said positive response rates in key measures reported at three months after treatment were sustained at 12 months after treatment.

"These positive long-term results are highly encouraging, indicating that the CTX therapy has the potential to produce meaningful and sustained improvements in disability as well as motor function in disabled stroke patients," it said.


At 9:51am: (LON:RENE) ReNeuron Group PLC share price was 0p at 1.68p



Related Charts

ReNeuron Group (RENE)

0.00 (0.00%)
delayed 16:57PM